Shares of Advaxis, Inc. (NASDAQ:ADXS) dropped 0% during mid-day trading on Thursday . The stock traded as low as $2.60 and last traded at $2.64. Approximately 1,361,024 shares were traded during trading, an increase of 51% from the average daily volume of 904,189 shares. The stock had previously closed at $2.64.
ADXS has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $23.00 target price on shares of Advaxis in a report on Wednesday, November 8th. Cantor Fitzgerald set a $19.00 target price on Advaxis and gave the stock a “buy” rating in a report on Thursday, December 28th. Finally, ValuEngine raised Advaxis from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
The stock has a market capitalization of $98.00, a PE ratio of -1.09 and a beta of 0.70.
Hedge funds and other institutional investors have recently made changes to their positions in the business. OxFORD Asset Management LLP acquired a new position in Advaxis during the second quarter worth approximately $498,000. Franklin Street Advisors Inc. NC increased its position in Advaxis by 117.1% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 129,800 shares of the biotechnology company’s stock worth $369,000 after buying an additional 70,000 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in Advaxis during the second quarter worth approximately $352,000. Vanguard Group Inc. increased its position in Advaxis by 7.2% during the second quarter. Vanguard Group Inc. now owns 1,782,990 shares of the biotechnology company’s stock worth $11,572,000 after buying an additional 119,980 shares during the last quarter. Finally, State Street Corp increased its position in Advaxis by 7.8% during the second quarter. State Street Corp now owns 670,134 shares of the biotechnology company’s stock worth $4,352,000 after buying an additional 48,485 shares during the last quarter. 42.63% of the stock is currently owned by hedge funds and other institutional investors.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.